Johnson & Johnson has appointed Thibaut Mongon as the chief executive of its consumer health division, which is scheduled to be spun off into a listed company by the end of 2023.
Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to troubled Alzheimer's therapy
Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company.
The board of Eikon Therapeutics will soon look like Merck & Co's a few years ago – after the big pharma's former CEO Ken Frazier agree to join his former colleagues Roger Perlmutter and
Merck & Co's chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roge